Ovid Therapeutics (OVID) Change in Cash (2016 - 2026)

Ovid Therapeutics (OVID) has reported Change in Cash for 11 consecutive years, with -$82.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Cash fell 1236.65% year-over-year to -$82.7 million; the trailing twelve-month figure through Jun 2026 stood at -$17.1 million (down 1236.04% YoY), and the FY2025 full-year result was -$13.1 million, down 1676.76% from the prior year.
• Change in Cash slipped to -$82.7 million in Q2 2026 per OVID's latest filing, from $80.9 million in the prior quarter.
• Across five years, Change in Cash topped out at $80.9 million in Q1 2026 and bottomed at -$93.9 million in Q2 2022.
• Historically, Change in Cash has averaged -$9.8 million across 5 years, with a median of -$7.6 million in 2025.
• The widest YoY moves for Change in Cash: up 1666.52% in 2026, down 1236.65% in 2026.
• Over 5 years, Change in Cash stood at -$13.4 million in 2022, then plunged by 127.01% to -$30.4 million in 2023, then jumped by 137.13% to $11.3 million in 2024, then sank by 166.09% to -$7.5 million in 2025, then sank by 1009.37% to -$82.7 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$82.7 million, $80.9 million, and -$7.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.